Skip to main
IDYA

IDYA Stock Forecast & Price Target

IDYA Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 42%
Buy 50%
Hold 8%
Sell 0%
Strong Sell 0%

Bulls say

IDEAYA Biosciences is a promising oncology-focused precision medicine company with a solid pipeline of multiple clinical-stage product candidates, including darovasertib, IDE397, IDE849, IDE275, IDE161, and IDE705. The company's approach of combining small molecule drug discovery with the use of biomarkers is a notable strength, and their focus on select patient populations likely to benefit from targeted therapies presents a significant opportunity for growth. With recent updates confirming positive results and the potential for continued advancements in their clinical programs, the company has a positive outlook for continued success in the years to come.

Bears say

IDEAYA Biosciences is an oncology-focused precision medicine company with a promising clinical pipeline of targeted therapeutics. However, competition in the space is high and IDEAYA's late start in Ph 3 trials compared to its competitors may limit its market share potential. Additionally, the company's financials, including a net loss of $23.8 million in the first quarter of 2021, suggest that it may face challenges in bringing its drugs to market successfully.

IDYA has been analyzed by 12 analysts, with a consensus rating of Buy. 42% of analysts recommend a Strong Buy, 50% recommend Buy, 8% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ideaya Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ideaya Biosciences Inc (IDYA) Forecast

Analysts have given IDYA a Buy based on their latest research and market trends.

According to 12 analysts, IDYA has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $54.58, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $54.58, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ideaya Biosciences Inc (IDYA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.